Organisation paid for research Program year 2025 Source: CMS Open Payments

Christie Clinic LLC

Neither a doctor nor a teaching hospital

Research payments

$125,496

84 payments

Through program year 2025, Christie Clinic LLC is reported as receiving $125,496 in research payments, across 84 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $797 1
2024 Research $757 1
2023 Research $743 1
2022 Research $77,124 30
2021 Research $11,292 30
2020 Research $16,082 13
2019 Research $18,701 8

Breakdown

Who paid Research payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $64,652 12 payments
  2. Esperion Therapeutics, Inc. $25,699 52 payments
  3. Pfizer Inc. $18,701 8 payments
  4. Regeneron Pharmaceuticals, Inc. $12,593 6 payments
  5. AbbVie, Inc. $3,026 5 payments
  6. Medical Device Business Services, Inc. $825 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Phase III, Randomized, Controlled, Observer-Blind Study to Evaluate $64,652 12 payments
  2. A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effects of Bempedoic Acid (Etc-1002) on the Occurrence of Major Cardiovascular Events in Patients With, Or at High Risk For, Cardiovascular Disease Who Are Statin Intolerant $25,699 52 payments
  3. A Phase 3 Randomized Doubleblind Placebocontrolled Multicenter Study Investigating the Efficacy and Safety Ofpf04965842 Coadministered With Background Medicated Topical Therapy in Adolescent Participants 12 to 18 Years of Age With Moderatetosevere Atopic Dermatitis $18,701 8 payments
  4. A Prospective Observational Study of Adult Patients Receiving Dupixent for Atopic Dermatitis $12,593 6 payments
  5. A Long-Term Registry of Humira (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC) $1,500 2 payments
  6. Data Provision Agreement to license de-identified patient-level to meet product-specific data submission requirements of regulatory authorities; under supervision of Dr. Kluesner MD. $825 1 payment
  7. A Long-Term Registry of Humira (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC) $797 1 payment
  8. A Long-Term Registry of Humira?? (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC) $729 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record